| Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.J Minim Invasive Gynecol | Pooled analysis | 2026 |
| Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.J Sex Res | Pooled analysis | 2021 |
| Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.Obstet Gynecol | Pooled analysis | 2018 |
| Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.J Womens Health (Larchmt) | Random groups | 2022 |
| Safety Profile of Bremelanotide Across the Clinical Development Program.J Womens Health (Larchmt) | Random groups | 2022 |
| The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.J Womens Health (Larchmt) | Random groups | 2021 |
| Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstet Gynecol | Random groups | 2019 |
| Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.J Sex Med | Random groups | 2019 |
| Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.J Hypertens | Random groups | 2017 |
| Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.Clin Ther | Random groups | 2017 |
| Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Womens Health (Lond) | Random groups | 2016 |
| RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.J Sex MedRetracted | Random groups | 2008 |
| Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.J Urol | Random groups | 2008 |
| An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.J Sex Med | Random groups | 2006 |
| Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.Urology | Random groups | 2005 |
| Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.Int J Impot Res | Random groups | 2004 |
| Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.Int J Impot Res | Random groups | 2004 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | No random groups | 2004 |
| PT-141: a melanocortin agonist for the treatment of sexual dysfunction.Ann N Y Acad Sci | No random groups | 2003 |
| Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study.J Gen Intern Med | Group followed over time | 2025 |
| First-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report.Sex Med | Case reports | 2023 |
| Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.Clin Toxicol (Phila) | Case reports | 2012 |
| Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.Sex Med Rev | Review of studies | 2026 |
| Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.J Minim Invasive Gynecol | Review of studies | 2026 |
| Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.Front Med (Lausanne) | Review of studies | 2026 |
| FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.Drug Dev Res | Review of studies | 2026 |
| Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci | Review of studies | 2026 |
| Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.Front Aging | Review of studies | 2026 |
| Quantification of "Mercy Sex" in Heterosexual Women.J Sex Marital Ther | Review of studies | 2026 |
| Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.Expert Rev Clin Pharmacol | Review of studies | 2025 |
| Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.Diseases | Review of studies | 2025 |
| 2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns.Support Care Cancer | Review of studies | 2025 |
| Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions.Expert Opin Pharmacother | Review of studies | 2025 |
| Novel Pharmacologic Treatments of Female Sexual Dysfunction.Clin Obstet Gynecol | Review of studies | 2025 |
| Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.Ann Pharmacother | Review of studies | 2025 |
| Understanding the Interplay Between Premenstrual Dysphoric Disorder (PMDD) and Female Sexual Dysfunction (FSD).Cureus | Review of studies | 2024 |
| Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.J Sex Res | Review of studies | 2024 |
| A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022).Cureus | Review of studies | 2024 |
| What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder.Pharmacology | Review of studies | 2024 |
| Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment.Cureus | Review of studies | 2023 |
| Targeting the central melanocortin system for the treatment of metabolic disorders.Nat Rev Endocrinol | Review of studies | 2023 |
| An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.Expert Opin Pharmacother | Review of studies | 2023 |
| Pharmacologic therapeutic options for sexual dysfunction.Curr Opin Obstet Gynecol | Review of studies | 2022 |
| Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin.Biomolecules | Review of studies | 2022 |
| Female sexual dysfunctions: an overview on the available therapeutic interventions.Minerva Obstet Gynecol | Review of studies | 2022 |
| The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.CNS Spectr | Review of studies | 2022 |
| Management of Hypertension with Female Sexual Dysfunction.Medicina (Kaunas) | Review of studies | 2022 |
| Medical Treatment of Female Sexual Dysfunction.Urol Clin North Am | Review of studies | 2022 |
| Pharmacotherapy for Sexual Dysfunction in Women.Curr Psychiatry Rep | Review of studies | 2022 |
| Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurol Int | Review of studies | 2022 |
| Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.Drug Ther Bull | Review of studies | 2021 |
| Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.J Midwifery Womens Health | Review of studies | 2021 |
| Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians.Int J Impot Res | Review of studies | 2020 |
| Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.Ann Pharmacother | Review of studies | 2020 |
| 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel) | Review of studies | 2020 |
| Bremelanotide: First Approval.Drugs | Review of studies | 2019 |
| Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.Med Lett Drugs Ther | Review of studies | 2019 |
| Expert opinion on existing and developing drugs to treat female sexual dysfunction.Expert Opin Emerg Drugs | Review of studies | 2018 |
| Effect Size in Efficacy Trials of Women With Decreased Sexual Desire.Sex Med Rev | Review of studies | 2018 |
| Evaluation and Management of Hypoactive Sexual Desire Disorder.Sex Med | Review of studies | 2018 |
| Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.J Sex Med | Review of studies | 2017 |
| Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder.Curr Sex Health Rep | Review of studies | 2017 |
| Flibanserin for hypoactive sexual desire disorder: place in therapy.Ther Adv Chronic Dis | Review of studies | 2017 |
| The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.CNS Drugs | Review of studies | 2015 |
| Drugs in early clinical development for the treatment of female sexual dysfunction.Expert Opin Investig Drugs | Review of studies | 2015 |
| Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.Expert Opin Investig Drugs | Review of studies | 2014 |
| Central nervous system agents and erectile dysfunction.Urol Clin North Am | Review of studies | 2011 |
| Clinical applications of centrally acting agents in male sexual dysfunction.Int J Impot Res | Review of studies | 2008 |
| Preclinical effects of melanocortins in male sexual dysfunction.Int J Impot Res | Review of studies | 2008 |
| Central nervous system-acting agents and the treatment of erectile and sexual dysfunction.Curr Urol Rep | Review of studies | 2007 |
| Clinical application of CNS-acting agents in FSD.J Sex Med | Review of studies | 2007 |
| Melanocortins in the treatment of male and female sexual dysfunction.Curr Top Med Chem | Review of studies | 2007 |
| Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.Peptides | Review of studies | 2006 |
| PT-141 Palatin.Curr Opin Investig Drugs | Review of studies | 2004 |
| A biodegradable suction patch for sustainable transbuccal peptide delivery.J Control Release | In animals | 2025 |
| Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.Neuropharmacology | In animals | 2025 |
| Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.J Pharm Biomed Anal | In animals | 2020 |
| Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro.Br J Pharmacol | In animals | 2008 |
| Bremelanotide: an overview of preclinical CNS effects on female sexual function.J Sex Med | In animals | 2007 |
| Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.Proc Natl Acad Sci U S A | In animals | 2004 |
| Salmonellae in gulls and other free-living birds in the Czech Republic.Cent Eur J Public Health | In animals | 1995 |
| Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.Anal Methods | Other paper | 2026 |
| Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.J Med Chem | Other paper | 2026 |
| Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?J Clin Psychopharmacol | Other paper | 2026 |
| FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.Turk J Biol | Other paper | 2025 |
| Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.Anticancer Res | Other paper | 2024 |
| Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.J Urol | Other paper | 2023 |
| Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?Expert Opin Pharmacother | Other paper | 2023 |
| Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.Diabetes Obes Metab | Other paper | 2022 |
| Structural insights into ligand recognition and activation of the melanocortin-4 receptor.Cell Res | Other paper | 2021 |
| Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".J Sex Res | Other paper | 2021 |
| Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.J Patient Rep Outcomes | Other paper | 2021 |
| Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder.J Patient Rep Outcomes | Other paper | 2020 |
| Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.J Womens Health (Larchmt) | Other paper | 2020 |
| Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.Obstet Gynecol | Other paper | 2019 |
| What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?Expert Opin Pharmacother | Other paper | 2019 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2008 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2008 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2007 |
| Melanocortin receptors, melanotropic peptides and penile erection.Curr Top Med Chem | Other paper | 2007 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2006 |
| Bremelanotide: the female Viagra?Expert Rev Endocrinol Metab | Other paper | 2006 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2005 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2005 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2005 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2004 |
| Gateways to clinical trials.Methods Find Exp Clin Pharmacol | Other paper | 2004 |
| [Therapy of erectile dysfunction in 2005].Urologe A | Other paper | 2003 |